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9.3% ≥ gr 3); diarrhoea (30.7%; 2.7% ≥ gr 3), dyspnoea (16.7%; 6.2% 
≥ gr 3) and anorexia (16%; 0.8% ≥ gr 3). Treatment discontinuation due 
to AEs occurred in 5.8% of patients, and 12% had dose reductions. 
Conclusions: MERIT is the largest ever prospective biomarker trial 
conducted in NSCLC. The results support the use of erlotinib (Tarce-
va®) as an effective and well tolerated alternative to chemotherapy for 
patients with advanced NSCLC who have failed at least one previous 
chemotherapy regimen. Data on the relationships between molecular 
markers and obtaining clinical beneﬁt with erlotinib will be presented.
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Background: Epidermal growth factor receptor (EGFR) gene copy 
number by ﬂuorescence in-situ hybridization (FISH) is a predictor of 
survival beneﬁt from EGFR inhibitor monotherapy, as demonstrated in 
prospective placebo-controlled clinical trials in advanced NSCLC. We 
aimed to investigate the predictive role of EGFR gene copy number in 
patients treated in a clinical study testing the combination of erlotinib 
and chemotherapy (TRIBUTE trial).
Methods: TRIBUTE was a phase III clinical trial that randomly as-
signed 1.059 patients to carboplatin and paclitaxel (CP) with erlotinib/
placebo followed by maintenance erlotinib/placebo. There was no dif-
ference in overall survival or progression-free survival between treat-
ment groups (P=0.95 and P=0.36, respectively). We analyzed 275 tissue 
samples from study participants (26% of study population) for EGFR 
gene copy number by FISH using commercially available EGFR/CEP7 
probe (Abbott Molecular, Des Plaines, IL, USA) and previously estab-
lished scoring criteria (Cappuzzo et al., 2005). 
Results: The results of EGFR FISH test were available for 245 
patients (89% of group subjected to analysis, including 121 patients 
who received erlotinib and 124 who received placebo). In this group 
of patients, time-to-progression (TTP) was not different between 
study arms but overall survival (OS) was longer for placebo than for 
erlotinib (median 13.2 months vs. 9.6 months, respectively, P=0.033). 
One hundred patients were EGFR FISH positive (FISH+, 40.8%). In 
the FISH+ subset, objective response rates to CP and erlotinib vs. CP 
and placebo were 11.6% and 29.8%, respectively (P=0.049). Response 
rates in FISH- subset of patients were 21.8% vs. 25.4%, respectively 
(P=0.695). In FISH+ patients, TTP was signiﬁcantly longer for 
erlotinib vs. placebo (HR=0.59, 95%CI: 0.35-0.99 log-rank P=0.043) 
and the difference was observed mainly after six months of treatment. 
There was no difference in OS (HR=1.52, 95% CI: 0.94-2.46, log-rank 
P=0.083). In FISH- patients, TTP and OS were not different between 
treatment arms (HR=1.42, 95%CI: 0.95-2.14, log-rank P=0.089 and 
HR=1.24, 95%CI: 0.84-1.82, log-rank P=0.278, respectively). The 
treatment by EGFR FISH interaction test was signiﬁcant for TTP 
(P=0.007) but not for OS (P=0.49).
Conclusion: EGFR gene copy number assessment by FISH may 
predict longer TTP in advanced NSCLC patients treated with ﬁrst-
line chemotherapy and erlotinib. This difference is seen mainly after 
completion of chemotherapy. The predictive value of EGFR FISH test 
on OS was not conﬁrmed. These exploratory results suggest the beneﬁt 
from maintenance erlotinib after completion of chemotherapy in FISH+ 
group of patients.
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Background: The role of speciﬁc EGFR genotypes and the efﬁcacy of 
treatment with geﬁtinib or erlotinib shows that patients with somatic 
exon 19 deletions are associated with longer time to progression and 
overall survival than patients with exon 21 point mutations. For other 
mutations in EGFR and KRAS, their speciﬁc role in sensitivity or 
resistance to treatment with an EGFR-TKI is less well described. In 
light of the relative infrequency of some of these mutations, we have 
created a mutation registry to track protocol-based clinical outcomes 
with speciﬁc mutations in previously untreated patients with NSCLC 
treated with erlotinib and geﬁtinb. By including only chemotherapy-
naïve patients, we are better able to judge the impact of EGFR-TKI 
therapy in tumors that have not been exposed to the effects of cytotoxic 
chemotherapeutic agents.
Methods: A web-based database has been created to compile the 
results of trials of EGFR-TKI therapy in chemotherapy-naïve patients. 
To date, three clinical trials have been included in this registry. In all 3 
trials, chemotherapy-naïve patients with Stage IIIB and IV NSCLC and 
PS 0-2 were treated with erlotinib 150 mg/d. One trial of 53 patients 
did not limit enrollment by any clinical or molecular characteristics. A 
second trial was limited to 80 patients age 70 or older. A third trial has 
accrued 49 women with adenocarcinoma who were former or never 
smokers; this trial mandated availability of tissue for EGFR and KRAS 
testing. 
Results: A total of 182 patients have been enrolled in these 3 trials 
from 2003 until the present; 112 patients were successfully screened 
for EGFR mutations, with 105 screened for KRAS. Table 1 includes 
the mutations detected, and the clinical outcomes associated with each 
genotype. The correlation between improved outcome and exon 19 
deletions and L858R mutations is again noted. In addition, the exon 19 
deletions are associated with improved TTP (16.6 vs 9.7 mo, p = .005) 
and OS (23+ vs 14.6 mo, p = .0002) compared with L858R mutations. 
Consistent with earlier literature, the association between resistance 
to erlotinib therapy and KRAS mutations, exon 20 insertions (1 pt, 
survival 1.5 months), and the T790M mutation (1 patient, survival 0.8 
months) is noted. Despite the small sample sizes, we did observe that 
codon 12 mutations of KRAS were associated with longer TTP (3.8 vs. 
1.2 mo, p=0.05) and OS (15.5 vs. 3.3 mo, p = .005) compared with the 
four patients with other KRAS mutations. 
